Teriparatide

also known as Forteo · PTH(1-34) · TPTD · Forsteo · Parathyroid Hormone (1-34) · rhPTH(1-34) · hPTH(1-34) · PTH · +11 more

Protein / enzyme biologic

Developed for: osteoporosis · postmenopausal osteoporosis · hypoparathyroidism · disease of bone structure · spinal cord injury · autosomal dominant hypocalcemia · bone resorption disease · chronic kidney disease
+18 more
· chronic renal failure syndrome · osteogenesis imperfecta · osteopetrosis · periodontitis · premenopausal osteoporosis · psoriasis · rheumatoid arthritis · secondary hypoparathyroidism due to impaired parathormon secretion · spinal stenosis · spondylolisthesis · spondylosis · anorexia nervosa · autoimmune polyendocrine syndrome type 1 · autosomal dominant hypocalcemia 1 · bone marrow disorder · bone remodeling disease · neurogenic arthropathy · osteoarthritis, knee
Investigated by: Eli Lilly and Company · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Entera Bio Ltd. · Massachusetts General Hospital · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · University of Pittsburgh
+89 more
· Asahi Kasei Therapeutics Corporation · Health Research, Inc. · Ministry of Defence, United Kingdom · Odense University Hospital · Pfenex, Inc · Thomas J. Schnitzer · University Hospital, Linkoeping · University of California, San Francisco · University of East Anglia · University of Michigan · Aalborg University Hospital · Amgen · Assistance Publique - Hôpitaux de Paris · Bio Sidus SA · Brigham and Women's Hospital · Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK) · Columbia University · Congressionally Directed Medical Research Programs · Copenhagen University Hospital, Denmark · Darlington Memorial Hospital · Ditte Hansen · Edward Hines Jr. VA Hospital · Esbjerg Hospital - University Hospital of Southern Denmark · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Fluminense Federal University · GlaxoSmithKline · Glostrup University Hospital, Copenhagen · Hartmut Malluche, MD · Helen Hayes Hospital · Helsinki University Central Hospital · Hospital for Special Surgery, New York · Khyber Medical University Peshawar · King Chulalongkorn Memorial Hospital · Leland Graves III, MD · M.D. Anderson Cancer Center · Manhattan Pharmaceuticals · Mayo Clinic · Medical Research Council of Southeast Sweden · Ministry of Health, France · National Heart, Lung, and Blood Institute (NHLBI) · National Institute for Health Research, United Kingdom · National Institute of Dental and Craniofacial Research (NIDCR) · Norfolk and Norwich University Hospitals NHS Foundation Trust · Northwestern University · Nottingham University Hospitals NHS Trust · Novartis · Odense Patient Data Explorative Network · Ohio Orthopedic Center of Excellence · Papageorgiou General Hospital · Paul F Netzel · Peking Union Medical College Hospital · Peking University Third Hospital · Pfizer · Post Graduate Institute of Medical Education and Research, Chandigarh · Region of Southern Denmark · Rigshospitalet, Denmark · Saint Petersburg State University, Russia · Salubris (Suzhou) Pharmaceutical Co., Ltd. · Seoul National University Bundang Hospital · Shane Burch · Sheffield Teaching Hospitals NHS Foundation Trust · Shenzhen Salubris Pharmaceuticals Co., Ltd. · Shinshu University · Shirley Ryan AbilityLab · Steno Diabetes Center Copenhagen · Susan L. Greenspan · Sygehus Lillebaelt · Syneos Health · The Danish Medical Research Council · The Emmes Company, LLC · The University of Hong Kong · Therapeutics, Inc. · TransPharma Medical · US Department of Veterans Affairs · all 95 on the full record

Regulatory milestones approvals, filings & regulatory actions · 5 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansion	US (FDA)	BONSITY	—	2023-11-16	fda.gov ↗
Label expansions (2)	US (FDA)	FORTEO	—	2009-07-22 – 2020-11-16	fda.gov ↗
Approved	EU (EMA)	Forsteo	—	2003-06-10	europa.eu ↗
Approved	US (FDA)	FORTEO	—	2002-11-26	fda.gov ↗

Trials 103 · started per year

today

US approved 2002

EU approved 2003

19911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT00377312	Sep 2006 → Dec 2007	hyperparathyroidism, osteoporosis	University of Pittsburgh	Completed	No outcome recorded
Phase 112 trials
Phase 1	NCT07497503	Apr → Sep 2026 expected	—	Syneos Health	Recruiting	No outcome recorded
Phase 1	NCT05965167	May 2023 → Feb 2026	disease of bone structure, hypoparathyroidism, osteoporosis	Entera Bio Ltd.	Completed	No outcome recorded
Phase 1	NCT02656810	Dec 2015 → Jul 2016	osteoporosis	Pfenex, Inc	Completed	No outcome recorded
Phase 1	NCT01333267	Jan 2015 → Jul 2017	humoral hypercalcemia of malignancy, hyperparathyroidism, osteoporosis	University of Pittsburgh	Withdrawn	No outcome recorded
Phase 1	NCT02571140	Oct 2013 → Aug 2017	—	Entera Bio Ltd.	Completed	No outcome recorded
Phase 1	NCT01935479	Aug 2013 → Feb 2014	osteoporosis	Asahi Kasei Therapeutics Corporation	Completed	No outcome recorded
Phase 1	NCT01551602	Mar → Sep 2012	osteoporosis	Asahi Kasei Therapeutics Corporation	Completed	No outcome recorded
Phase 1	NCT01250145	Nov 2010 → May 2011	postmenopausal osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 1	NCT00676312	May → Aug 2008	postmenopausal osteoporosis	Novartis	Completed	No outcome recorded
Phase 1	NCT00532077	Aug 2007 → Jan 2008	osteoporosis	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00277706	Aug 2004 → Jul 2009	bone resorption disease, periodontitis	University of Michigan	Completed	No outcome recorded
Phase 1	NCT00145886	Feb 2003 → Sep 2011	osteopetrosis	University of Chicago	Terminated	No outcome recorded

Phase 1/21 trial
Phase 1/2	NCT06303284	Jan 2025 → Dec 2026 expected	—	University of Calgary	Not yet recruiting	No outcome recorded
Phase 224 trials
Phase 2	NCT07579936	Apr → Jul 2026 overdue	postmenopausal osteoporosis	Shenzhen Salubris Pharmaceuticals Co., Ltd.	Recruiting	No outcome recorded
Phase 2	NCT04473989	Jun 2021 → Dec 2023	—	Peking University Third Hospital	Unknown	No outcome recorded
Phase 2	NCT02824718	Jun 2017 → May 2020	autosomal dominant hypocalcemia	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 2	NCT02972424	May 2017 → Mar 2021	osteoporosis	Hospital for Special Surgery, New York	Completed	No outcome recorded
Phase 2	NCT02152228	Jul 2014 → Jun 2015	hypoparathyroidism	Entera Bio Ltd.	Completed	No outcome recorded
Phase 2	NCT02025179	Jan 2013 → Aug 2015	disease of bone structure, osteoporosis, spinal cord injury	Northwestern University	Completed	No outcome recorded
Phase 2	NCT01679080	Nov 2012 → Jul 2020	osteogenesis imperfecta	University of Aarhus	Terminated	No outcome recorded
Phase 2	NCT01279187	Feb 2011 → Mar 2015	—	University of Michigan	Terminated	No outcome recorded
Phase 2	NCT01171690	Nov 2010 → Dec 2013	secondary hypoparathyroidism due to impaired parathormon secretion	Mayo Clinic	Terminated	No outcome recorded
Phase 2	NCT01225055	Oct 2010 → Aug 2015	disease of bone structure, osteoporosis, spinal cord injury	Thomas J. Schnitzer	Completed	No outcome recorded
Phase 2	NCT00926380	Jun 2009 → Dec 2016	postmenopausal osteoporosis	Massachusetts General Hospital	Completed	No outcome recorded
Phase 2	NCT00741182	Oct 2008 → Sep 2010	—	Glostrup University Hospital, Copenhagen	Withdrawn	No outcome recorded
Phase 2	NCT00623974	May 2008 → Jun 2010	—	M.D. Anderson Cancer Center	Terminated	No outcome recorded
Phase 2	NCT00535860	Apr 2008 → Mar 2009	osteoporosis	TransPharma Medical	Completed	No outcome recorded
Phase 2	NCT00593177	Oct 2007 → Jun 2008	psoriasis	Manhattan Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00393380	Sep 2006 → Nov 2009	Hodgkins lymphoma, acute myeloid leukemia, aplastic anemia, chronic lymphocytic leukemia/small lymphocytic lymphoma +2	The Emmes Company, LLC	Terminated	No outcome recorded
Phase 2	NCT00668941	Sep 2005 → Feb 2016	osteoporosis	Helen Hayes Hospital	Unknown	No outcome recorded
Phase 2	NCT00191867	Feb 2005 → Mar 2006	osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 2	NCT00190944	Dec 2004 → Jun 2007	—	Eli Lilly and Company	Completed	No outcome recorded
Phase 2	NCT00086619	May 2004 → Dec 2009	postmenopausal osteoporosis	Massachusetts General Hospital	Completed	No outcome recorded
Phase 2	NCT00004993	Aug 1999 → Aug 2001	osteoporosis	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	No outcome recorded
Phase 2	NCT00000400	Aug 1999 → Apr 2006	osteoporosis	Massachusetts General Hospital	Completed	No outcome recorded
Phase 2	NCT00018447	Nov 1998 → Oct 2003	postmenopausal osteoporosis	US Department of Veterans Affairs	Completed	No outcome recorded
Phase 2	NCT00001304	Oct 1991 → Mar 2014	hypoparathyroidism	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Completed	No outcome recorded

Phase 2/31 trial
Phase 2/3	NCT00697463	Aug 2008 → Jan 2012	premenopausal osteoporosis	Columbia University	Completed	No outcome recorded
Phase 323 trials
Phase 3	NCT04921124	May → Jul 2021	—	Norfolk and Norwich University Hospitals NHS Foundation Trust	Completed	No outcome recorded
Phase 3	NCT04750460	Mar 2021 → Feb 2022	hypoparathyroidism, renal osteodystrophy	Saint Petersburg State University, Russia	Completed	No outcome recorded
Phase 3	NCT04196855	Dec 2019 → Jun 2022	—	University of East Anglia	Unknown	No outcome recorded
Phase 3	NCT03133195	May 2017 → Jun 2022	—	King Chulalongkorn Memorial Hospital	Completed	No outcome recorded
Phase 3	NCT03002428	Dec 2016 → May 2018	osteoporosis	Pfenex, Inc	Completed	No outcome recorded
Phase 3	NCT01801397	Mar 2014 → Jun 2016	osteoporosis	University of Zurich	Unknown	No outcome recorded
Phase 3	NCT01473589	Feb 2012 → Dec 2013	—	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT01473602	Jan 2012 → Nov 2013	—	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00503399	Jul 2007 → Oct 2010	osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00433160	Jan 2007 → Sep 2008	osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00414973	Dec 2006 → Jul 2008	osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00395538	Oct 2006 → Sep 2017	DiGeorge syndrome, hypoparathyroidism	National Institute of Dental and Craniofacial Research (NIDCR)	Terminated	No outcome recorded
Phase 3	NCT00343252	Jun 2006 → Jun 2009	postmenopausal osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00500409	Dec 2005 → Dec 2006	osteoporosis	Virchow Group	Completed	No outcome recorded
Phase 3	NCT00191321	Jul 2004 → Dec 2005	osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00065637	Dec 2003 → Sep 2005	osteoporosis	University of California, San Francisco	Completed	No outcome recorded
Phase 3	NCT00532207	Nov 2003 → Dec 2004	postmenopausal osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00191802	Sep 2003 → Oct 2005	osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00191893	Sep 2003 → Nov 2006	osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00543023	Jun 2003 → Aug 2004	postmenopausal osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00051558	Nov 2002 → Jul 2006	osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00670501	Aug 1996 → Apr 1999	postmenopausal osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00046137	—	postmenopausal osteoporosis	Eli Lilly and Company	Completed	No outcome recorded

Phase 432 trials
Phase 4	NCT06264609	Feb 2024 → Dec 2029 expected	osteoporosis	Paul F Netzel	Enrolling by invitation	No outcome recorded
Phase 4	NCT06061354	Aug 2023 → Aug 2024	—	Universidad de Valparaiso	Unknown	No outcome recorded
Phase 4	NCT04522622	Dec 2021 → Sep 2026 expected	chronic kidney disease, heart disorder, renal osteodystrophy	Ditte Hansen	Recruiting	No outcome recorded
Phase 4	NCT03994172	Jul 2019 → Jun 2025 overdue	osteoporosis	VA Office of Research and Development	Active not recruiting	No outcome recorded
Phase 4	NCT02955056	Oct 2016 → Oct 2017	—	Nottingham University Hospitals NHS Trust	Unknown	No outcome recorded
Phase 4	NCT02156960	May 2014 → May 2015	osteoporosis	Shinshu University	Unknown	No outcome recorded
Phase 4	NCT04241211	Jan 2014 → Dec 2018	—	Seoul National University Bundang Hospital	Unknown	No outcome recorded
Phase 4	NCT02130973	Aug 2013 → Aug 2018	osteoporosis	Health Research, Inc.	Unknown	No outcome recorded
Phase 4	NCT01945788	Jun 2013 → Oct 2014	postmenopausal osteoporosis	Bio Sidus SA	Unknown	No outcome recorded
Phase 4	NCT01753856	Jan 2013 → Jun 2014	osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT01705587	Dec 2012 → Sep 2016	osteoporosis	Susan L. Greenspan	Completed	No outcome recorded
Phase 4	NCT01709110	Oct 2012 → Jul 2016	postmenopausal osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT02090244	Aug 2012 → May 2018	spinal stenosis	University Hospital, Linkoeping	Completed	No outcome recorded
Phase 4	NCT01430104	Aug → Dec 2011	osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT01292252	Aug 2011 → Dec 2015	spondylolisthesis, spondylosis	Shane Burch	Completed	No outcome recorded
Phase 4	NCT01400516	Aug 2011 → Jul 2015	rheumatoid arthritis	Brigham and Women's Hospital	Completed	No outcome recorded
Phase 4	NCT01360424	May 2011 → Nov 2013	osteoporosis	Helsinki University Central Hospital	Completed	No outcome recorded
Phase 4	NCT01293292	Jan 2011 → Aug 2015	osteoporosis	Sheffield Teaching Hospitals NHS Foundation Trust	Completed	No outcome recorded
Phase 4	NCT01173081	Jul 2010 → Apr 2014	—	Ohio Orthopedic Center of Excellence	Unknown	No outcome recorded
Phase 4	NCT01105832	Apr 2010 → Feb 2014	—	University Hospital, Linkoeping	Completed	No outcome recorded
Phase 4	NCT00927186	Jul 2009 → Oct 2010	postmenopausal osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00826228	Jun 2009 → Mar 2012	disease of bone structure, osteoporosis, spinal cord injury	Thomas J. Schnitzer	Completed	No outcome recorded
Phase 4	NCT00887354	Apr 2009 → Aug 2015	osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00557310	Nov 2007 → Oct 2010	postmenopausal osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00446589	Jul 2006 → ?	osteoporosis	Papageorgiou General Hospital	Terminated	No outcome recorded
Phase 4	NCT00259298	Nov 2005 → Jul 2009	osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00239629	Sep 2005 → Jan 2007	postmenopausal osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00079924	Nov 2004 → May 2007	postmenopausal osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00532545	Apr 2003 → Apr 2004	postmenopausal osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00191425	Aug 2002 → Nov 2005	postmenopausal osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00035256	Oct 2001 → Jul 2005	postmenopausal osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT02416271	Apr 2001 → May 2003	osteoporosis	Eli Lilly and Company	Completed	No outcome recorded

Phase not applicable9 trials
—	NCT07242612	Oct 2025 → Mar 2026 overdue	postmenopausal osteoporosis	Khyber Medical University Peshawar	Recruiting	No outcome recorded
—	NCT05866029	May 2023 → Sep 2026 expected	osteoporosis	Peking Union Medical College Hospital	Recruiting	No outcome recorded
—	NCT03770338	Mar 2019 → Mar 2026 overdue	osteoporosis	The University of Hong Kong	Active not recruiting	No outcome recorded
—	NCT02563353	Nov 2015 → Nov 2018	osteoporosis	Odense University Hospital	Completed	No outcome recorded
—	NCT02440581	Jul 2015 → Jun 2021	chronic renal failure syndrome	Hartmut Malluche, MD	Completed	No outcome recorded
—	NCT01760798	Jan 2012 → Jun 2014	osteoporosis	Post Graduate Institute of Medical Education and Research, Chandigarh	Unknown	No outcome recorded
—	NCT00754442	Feb 2007 → Aug 2008	non-renal secondary hyperparathyroidism	University of Maryland, Baltimore	Completed	No outcome recorded
—	NCT00365924	Dec 2006 → Apr 2008	osteoporosis	Pfizer	Completed	No outcome recorded
—	NCT00347737	Jun 2006 → May 2008	osteoporosis	Leland Graves III, MD	Withdrawn	No outcome recorded

Also used as a comparator or background therapy in 51 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 15 trials
Phase 1	NCT05164614 Comparator	Feb → Oct 2022	—	RANI Therapeutics	Completed	No outcome recorded
Phase 1	NCT01913834 Comparator	Sep 2013 → Aug 2014	osteoporosis	Nottingham University Hospitals NHS Trust	Unknown	No outcome recorded
Phase 1	NCT02202603 Comparator	Jul 2011 → Aug 2013	—	Entera Bio Ltd.	Completed	No outcome recorded
Phase 1	NCT01224717 Comparator	Sep 2010 → Apr 2011	postmenopausal osteoporosis	Novartis	Completed	No outcome recorded
Phase 1	NCT02223416 Comparator	? → Jan 2015	—	Gedeon Richter Plc.	Completed	No outcome recorded
Phase 1/21 trial
Phase 1/2	NCT03720886 Comparator	Oct 2018 → May 2020	postmenopausal osteoporosis	Shenzhen Salubris Pharmaceuticals Co., Ltd.	Unknown	No outcome recorded
Phase 218 trials
Phase 2	NCT05018637 Background	Sep 2020 → Dec 2022	osteoporosis, vertebral disorder	Inbo Han	Unknown	No outcome recorded
Phase 2	NCT03702140 Comparator	Oct 2018 → Oct 2023	osteoporosis	Shinshu University	Unknown	No outcome recorded
Phase 2	NCT03072147 Comparator	May 2017 → Sep 2022	osteoarthritis, knee	Christopher Ritchlin	Completed	No outcome recorded
Phase 2	NCT02023411 Comparator	Jan 2014 → Dec 2018	neurogenic arthropathy	Post Graduate Institute of Medical Education and Research, Chandigarh	Completed	No outcome recorded
Phase 2	NCT01440803 Comparator	Aug 2012 → Jan 2018	premenopausal osteoporosis	Elizabeth Shane	Completed	No outcome recorded
Phase 2	NCT01604057 Comparator	Nov 2011 → Jul 2012	osteoporosis	Azelon Pharmaceuticals	Unknown	No outcome recorded
Phase 2	NCT01321723 Comparator	Feb → Oct 2011	postmenopausal osteoporosis	Unigene Laboratories Inc.	Completed	No outcome recorded
Phase 2	NCT01063504 Comparator	Feb 2010 → Jun 2013	osteoarthritis, knee	University Hospital, Linkoeping	Completed	No outcome recorded
Phase 2	NCT01011556 Comparator	Nov 2009 → Sep 2011	osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 2	NCT00896532 Comparator	Jun 2009 → Feb 2011	postmenopausal osteoporosis	Amgen	Completed	No outcome recorded
Phase 2	NCT00853723 Comparator	May 2009 → Feb 2012	osteoporosis	University of Pittsburgh	Completed	No outcome recorded
Phase 2	NCT00759772 Comparator	Sep 2008 → Feb 2016	anorexia nervosa, osteoporosis	Massachusetts General Hospital	Completed	No outcome recorded
Phase 2	NCT00743782 Comparator	Aug 2008 → Apr 2014	autoimmune polyendocrine syndrome type 1, autosomal dominant hypocalcemia 1	National Institutes of Health Clinical Center (CC)	Completed	No outcome recorded
Phase 2	NCT00624481 Comparator	Mar 2008 → Apr 2009	osteoporosis	Nastech Pharmaceutical Company, Inc.	Withdrawn	No outcome recorded
Phase 2	NCT00489918 Comparator	Jun 2007 → Apr 2008	osteoporosis	Zosano Pharma Corporation	Completed	No outcome recorded
Phase 2	NCT00471237 Comparator	May 2007 → Dec 2008	osteoporosis	GlaxoSmithKline	Terminated	No outcome recorded
Phase 2	NCT00542425 Comparator	Apr 2007 → Jun 2009	osteoporosis	Radius Health, Inc.	Completed	No outcome recorded
Phase 2	NCT00005006 Comparator	Sep 1987 → Feb 2003	osteoporosis	Helen Hayes Hospital	Completed	No outcome recorded

Phase 310 trials
Phase 3	NCT06898060 Comparator	Jun 2025 → May 2027 expected	postmenopausal osteoporosis	Qilu Pharmaceutical Co., Ltd.	Not yet recruiting	No outcome recorded
Phase 3	NCT02091492 Comparator	Jun 2014 → Sep 2015	osteoporosis	Medical University of Vienna	Withdrawn	No outcome recorded
Phase 3	NCT01896011 Comparator	Jul 2013 → Dec 2021	—	University Health Network, Toronto	Completed	No outcome recorded
Phase 3	NCT01796301 Comparator	Jan 2013 → May 2015	postmenopausal osteoporosis	Amgen	Completed	No outcome recorded
Phase 3	NCT01343004 Comparator	Apr 2011 → Oct 2014	postmenopausal osteoporosis	Radius Health, Inc.	Completed	No outcome recorded
Phase 3	NCT00577863 Background	Jan → May 2008	osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00439244 Comparator	Dec 2006 → Feb 2009	osteoporosis	Novartis	Completed	No outcome recorded
Phase 3	NCT01611571 Comparator	Dec 2003 → Nov 2011	osteoporosis	Columbia University	Completed	No outcome recorded
Phase 3	NCT00542984 Comparator	Aug 2003 → Nov 2004	postmenopausal osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00543218 Comparator	Dec 2002 → Jun 2004	postmenopausal osteoporosis	Eli Lilly and Company	Completed	No outcome recorded

Phase 413 trials
Phase 4	NCT06558188 Comparator	Feb 2025 → Dec 2027 expected	postmenopausal osteoporosis	Massachusetts General Hospital	Recruiting	No outcome recorded
Phase 4	NCT04589819 Comparator	Dec 2022 → Dec 2026 expected	—	University of South Carolina	Enrolling by invitation	No outcome recorded
Phase 4	NCT05151484 Comparator	Mar 2022 → Jan 2027 expected	osteoporosis	Madhumathi Rao	Active not recruiting	No outcome recorded
Phase 4	NCT04026256 Comparator	Sep 2019 → Apr 2022	postmenopausal osteoporosis	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT03472846 Comparator	Mar 2017 → Sep 2022	postmenopausal osteoporosis, type 2 diabetes mellitus	Medical University of Vienna	Completed	No outcome recorded
Phase 4	NCT03735537 Comparator	Nov 2016 → Feb 2025	osteogenesis imperfecta	University of Edinburgh	Completed	No outcome recorded
Phase 4	NCT02176382 Comparator	Aug 2014 → Feb 2020	postmenopausal osteoporosis	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT01750086 Comparator	Jan 2013 → Apr 2014	postmenopausal osteoporosis	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT01734824 Comparator	May 2012 → Sep 2015	bone marrow disorder, bone remodeling disease	Medical University of Vienna	Suspended	No outcome recorded
Phase 4	NCT01166958 Comparator	Sep 2010 → Nov 2012	osteoporosis	University of Wisconsin, Madison	Completed	No outcome recorded
Phase 4	NCT01153425 Comparator	Jul 2008 → Dec 2012	osteoporosis	University of Pennsylvania	Completed	No outcome recorded
Phase 4	NCT01535027 Comparator	Mar 2006 → Dec 2012	osteoporosis	Medical University of Vienna	Completed	No outcome recorded
Phase 4	NCT00131469 Comparator	Jun 2005 → Jan 2011	osteogenesis imperfecta	Oregon Health and Science University	Completed	No outcome recorded

Phase not applicable4 trials
—	NCT04669782 Background	Nov 2020 → Jul 2024	osteoporosis	University of Milano Bicocca	Terminated	No outcome recorded
—	NCT01656629 Comparator	Aug 2012 → Jun 2014	osteoporosis	Johns Hopkins University	Terminated	No outcome recorded
—	NCT01309399 Comparator	Aug 2010 → Nov 2014	osteoporosis	Health Research, Inc.	Completed	No outcome recorded
—	NCT00594906 Comparator	Jan 2008 → Jul 2012	—	University of Rochester	Terminated	No outcome recorded

Press releases naming this drug 4 releases

Date	Issuer	Release
2023-11-17	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S. tevapharm.com ↗
2016-04-01	Amgen	Amgen And UCB Present Positive Data At ENDO 2016 Comparing Romosozumab With Teriparatide amgen.com ↗
2015-10-12	Amgen	New Exploratory Analysis Showed Romosozumab Increased Estimated Bone Strength More Than Teriparatide amgen.com ↗
2015-09-01	Amgen	Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide amgen.com ↗

Evidence & citations 23 cited values

Every value below carries the sentence it was read from. 163 sources stand behind the page.

Field	Value	Cited text
Known as	Teriparatide	“This study is a Phase 1, multi-center, 2-part, subject- and investigator-blind, randomized, placebo-controlled, multiple dose study of transdermal teriparatide (80-µg dose) in...” NCT01250145 ↗ 131 “Teriparatide (TP), a recombinant human parathyroid hormone (PTH 1-34), is a bone forming agent mainly used to treat osteoporotic patients with high risk of osteoporotic fracture.” NCT04241211 ↗ “Teriparatide (recombinant human parathyroid hormone [1-34]) increases bone formation and improves bone microarchitecture, thereby reducing the risk of fractures.” PMID 18822620 ↗ Jun 2008 “This longitudinal clinical trial assessed outcomes of periodontal surgery and teriparatide administration in vitamin-D-sufficient and -insufficient individuals.” PMID 21555774 ↗ May 2011 “Teriparatide is a drug currently prescribed for some osteoporosis patients by their doctor to be taken by injection.” NCT01913834 ↗ “Teriparatide Injection daily formulation administered for 2 weeks, followed by SAL056 for 6 weeks.” NCT07579936 ↗ “The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab” NCT02130973 ↗ “the sub-cutaneous form of teriparatide, the active ingredient in PTH134” NCT01224717 ↗ “Teriparatide (Forsteo®), 20µg s.c. daily for 24 months.” NCT01801397 ↗ “transdermal administration of teriparatide acetate” NCT01551602 ↗ “Forsteo (Teriparatide)” NCT01321723 ↗ NCT00927186 ↗ NCT03994172 ↗ NCT02176382 ↗ NCT01153425 ↗ NCT00624481 ↗ NCT00446589 ↗ NCT02023411 ↗ NCT00697463 ↗ NCT01292252 ↗ NCT04026256 ↗ NCT00191802 ↗ NCT01430104 ↗ NCT06558188 ↗ NCT01400516 ↗ NCT04473989 ↗ NCT00065637 ↗ NCT00670501 ↗ NCT01225055 ↗ NCT01896011 ↗ NCT04750460 ↗ NCT06061354 ↗ NCT07242612 ↗ NCT03002428 ↗ NCT01945788 ↗ NCT00532207 ↗ NCT02972424 ↗ NCT01440803 ↗ NCT02202603 ↗ NCT01705587 ↗ NCT02416271 ↗ NCT04522622 ↗ NCT00190944 ↗ NCT03133195 ↗ NCT02091492 ↗ NCT01796301 ↗ NCT04921124 ↗ NCT00414973 ↗ NCT00259298 ↗ NCT00503399 ↗ NCT00754442 ↗ NCT00926380 ↗ NCT02656810 ↗ NCT05866029 ↗ NCT03472846 ↗ NCT01656629 ↗ NCT00191867 ↗ NCT01709110 ↗ NCT00347737 ↗ NCT00542425 ↗ NCT04589819 ↗ NCT00191893 ↗ NCT01750086 ↗ NCT00543023 ↗ NCT01734824 ↗ NCT00035256 ↗ NCT00051558 ↗ NCT03770338 ↗ NCT00532545 ↗ NCT00557310 ↗ NCT00433160 ↗ NCT02156960 ↗ NCT01360424 ↗ NCT05018637 ↗ NCT01753856 ↗ NCT01011556 ↗ NCT01604057 ↗ NCT01063504 ↗ NCT01611571 ↗ NCT03720886 ↗ NCT00393380 ↗ NCT00005006 ↗ NCT01309399 ↗ NCT00594906 ↗ NCT00131469 ↗ NCT01279187 ↗ NCT01473602 ↗ NCT03702140 ↗ NCT02090244 ↗ NCT00623974 ↗ NCT01171690 ↗ NCT01343004 ↗ NCT02571140 ↗ NCT00239629 ↗ NCT00489918 ↗ NCT01166958 ↗ NCT00826228 ↗ NCT01679080 ↗ NCT05151484 ↗ NCT01535027 ↗ NCT00759772 ↗ NCT03072147 ↗ NCT06303284 ↗ NCT00046137 ↗ NCT00543218 ↗ NCT00542984 ↗ NCT02824718 ↗ NCT02440581 ↗ NCT03735537 ↗ NCT02025179 ↗ NCT00439244 ↗ NCT00079924 ↗ NCT01473589 ↗ NCT01173081 ↗ NCT01105832 ↗ NCT00668941 ↗ NCT06264609 ↗ NCT00896532 ↗ NCT02223416 ↗ NCT00535860 ↗ NCT01293292 ↗ NCT04669782 ↗ NCT04196855 ↗ NCT00471237 ↗ NCT00887354 ↗ NCT00191425 ↗ NCT00577863 ↗ NCT02563353 ↗ NCT01760798 ↗ NCT00343252 ↗ NCT06898060 ↗ NCT00191321 ↗
Known as	AK159	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01935479 ↗
Known as	Forsteo	“Patients were administered 20mcg of TP (Forsteo) subcutaneously once a day from the day between before 3months to after 3months about surgery.” NCT04241211 ↗ 6 “in comparison to Forsteo®, the sub-cutaneous form of teriparatide” NCT01224717 ↗ “Teriparatide (Forsteo) 20 micrograms daily during four weeks” NCT01105832 ↗ “Teriparatide (Forsteo®), 20µg s.c. daily for 24 months.” NCT01801397 ↗ NCT02955056 ↗ NCT01321723 ↗ NCT07497503 ↗
Known as	Forteo	“Each side will be grafted with Bio-Oss® or Bio-Oss® combined with 1 dose (20 µg) of teriparatide (Forteo®).” NCT06061354 ↗ 13 “The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab” NCT02130973 ↗ “teriparatide (Forteo) has been shown to improve bone mass and microarchitecture” NCT01440803 ↗ “has been approved for the treatment of osteoporosis as FORTEO by Eli Lilly” NCT00277706 ↗ “daily injections with 20 µg teriparatide (PTH 1-34 (Forteo)) for 4 weeks” PMID 26179771 ↗ Jul 2015 “30 participants will receive teriparatide (Forteo) injection pens.” NCT00594906 ↗ “Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months” NCT02025179 ↗ “two teriparatide products (PF708 and Forteo)” NCT02656810 ↗ “"Teriparatide", "Forteo® or Teribon"” NCT03702140 ↗ “Drug: Teriparatide (Forteo)” NCT03002428 ↗ “Teriparatide Forteo” NCT01945788 ↗ NCT05965167 ↗ NCT05164614 ↗ NCT00365924 ↗
Known as	hPTH(1-34)	“We therefore developed 7-day continuous-infusion models using human parathyroid hormone(1-34) [hPTH(1-34)] and human parathyroid hormone-related protein(1-36) [hPTHrP(1-36)] in...” PMID 21544866 ↗ Sep 2011 2 “Parathyroid hormone (hPTH 1-34)” NCT00004993 ↗ NCT00086619 ↗
Known as	Human parathyroid hormone [hPTH-(1-34)]	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00000400 ↗
Known as	human parathyroid hormone(1-34)	“We therefore developed 7-day continuous-infusion models using human parathyroid hormone(1-34) [hPTH(1-34)] and human parathyroid hormone-related protein(1-36) [hPTHrP(1-36)] in...” PMID 21544866 ↗ Sep 2011
Known as	Osteofortil	“Teriparatide Osteofortil” NCT01945788 ↗
Known as	Parathyroid Hormone (1-34)	“Parathyroid hormone (1-34), when given as a daily injection has been found to dramatically increase bone mass in osteoporotic animals and postmenopausal women.” NCT00004993 ↗ 5 “A Phase I Study to Evaluate the Pharmacokinetics of Parathyroid Hormone (1-34) Administered Orally Via RaniPill™ Capsule” NCT05164614 ↗ “Oral administration of EnteraBio's Oral Parathyroid Hormone (1-34)” NCT02152228 ↗ NCT00853723 ↗ NCT00377312 ↗ NCT01333267 ↗
Known as	PF708	“Drug: Teriparatide (PF708)” NCT03002428 ↗
Known as	PTH	“evaluating the pharmacokinetics (PK) of human parathyroid hormone (1-34) ("PTH") administered via the RaniPill™ capsule ("RT-102")” NCT05164614 ↗ 1 “received Synthetic Human Parathyroid Hormone 1-34 (PTH) delivered through an insulin pump” NCT00743782 ↗
Known as	PTH(1-34)	“There is only one anabolic agent that is presently approved by the FDA for treatment for osteoporosis: parathyroid hormone, PTH (1-34), or teriparatide.” NCT00853723 ↗ 10 “Teriparatide or PTH 1-34 is a 34 amino acid peptide derived by recombinant DNA technology from the authentic sequence of human parathyroid hormone.” NCT03994172 ↗ “Teriparatide (PTH 1-34) treatment increases peripheral hematopoietic stem cells in postmenopausal women” PMID 24420643 ↗ Jun 2014 “an oral PTH (1-34) preparation produced by Entera Bio” NCT02152228 ↗ “PTH(1-34) IV given over a one week period” NCT00377312 ↗ “Teriparatide (PTH 1-34)” NCT00697463 ↗ NCT01224717 ↗ NCT00395538 ↗ NCT00018447 ↗ NCT00593177 ↗ NCT00676312 ↗
Known as	rhPTH	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00145886 ↗
Known as	rhPTH(1-34)	“Teriparatide, rhPTH(1-34), produced in E. coli, using recombinant DNA technology, is identical to the 34-N-terminal amino acid sequence of endogenous human parathyroid hormone.” NCT04196855 ↗ 4 “standard treatment + Forsteo (rhPTH 1-34) during 4 weeks” NCT01105832 ↗ NCT00532077 ↗ NCT00741182 ↗ NCT03720886 ↗
Known as	Synthetic Human Parathyroid Hormone 1-34	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001304 ↗ 1 NCT00743782 ↗
Known as	Teribon	“"Teriparatide", "Forteo® or Teribon"” NCT03702140 ↗
Known as	Teribone	“56.5μg teriparatide acetate(Teribone™) administered by subcutaneous injection once a week for 24 weeks.” NCT03720886 ↗
Known as	Teriparatide (brand name: Forteo)	“Teriparatide (brand name: Forteo)” NCT00853723 ↗
Known as	teriparatide acetate	“56.5μg teriparatide acetate(Teribone™) administered by subcutaneous injection once a week for 24 weeks.” NCT03720886 ↗
Known as	TPTD	“In order to maximize the early anabolic effect with teriparatide (TPTD), and to avoid the development of tachyphylaxis to the continued daily administration of TPTD beyond 6...” NCT02130973 ↗ 7 “PURPOSE: To evaluate the effects of cyclic vs daily teriparatide treatment (TPTD) on volumetric bone mineral density (vBMD) and bone strength at the hip and spine in women who...” PMID 36410666 ↗ Nov 2022 “Treatment of osteoporosis with an anabolic agent, teriparatide [human PTH 1-34 (TPTD)], is effective in reducing incident fractures, but patient resistance to daily sc...” PMID 19858319 ↗ Oct 2009 “Teriparatide (TPTD) increases skeletal mass, bone turnover markers, and bone strength, but in vivo effects at individual skeletal sites have not been characterized.” PMID 19929434 ↗ May 2010 “INTRODUCTION: To determine if teriparatide (20 μg/day; TPTD) results in improved radiologic healing, reduced pain, and improved functional outcome vs placebo” PMID 34383100 ↗ Aug 2021 “Teriparatide (TPTD) or PTH 1-34 which will be obtained from commercial sources and given at 20 mcg daily, by SC injection.” NCT03994172 ↗ “human recombinant parathyroid hormone (hPTH) 1-34 (or teriparatide (TPTD))” NCT01440803 ↗ “Teriparatide (TPTD) 20mcg daily using Teriparatide Pen Injector” NCT03735537 ↗
Action	Restore	“therapeutic PTH replacement” NCT00001304 ↗
Modality	Protein / enzyme biologic	“79 adults with OI were randomized to receive 20 μg recombinant human parathyroid hormone (teriparatide) or placebo for 18 months” PMID 24463451 ↗ Jan 2014
Route	Subcutaneous	“self-administered sc injection” NCT00000400 ↗